Key update sent Voyager Therapeutics (VYGR) stock go bullish in the After-hours
Voyager Therapeutics (Nasdaq: VYGR) shares dropped -14.73% to $7.7 in the After-market session on Tuesday after the U.S. Neurocrine Biosciences (Nasdaq: NBIX) has been told by the Food and Drug Administration (FDA) that it has put a clinical hold on the NBIb-1817b clinical trial RESTORE-1 (VY-AADC). It was previously disclosed that sites participating in RESTORE-1 […]